MyBlueDots

Research shows sotagliflozin is the first medication of its kind to significantly reduce both heart attacks and strokes

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart attack and stroke among these patients, according to results from an international clinical trial led by a Mount Sinai researcher.
Read More

Comprehensive CT scans may help identify atherosclerosis among lung cancer patients

Several cardiovascular risk factors, such as advanced age and smoking history, are prevalent among lung cancer patients at the time of the diagnosis and increase their risk of future heart disease, according to a new study being presented at ACC’s Advancing the Cardiovascular Care of the Oncology Patient course. Comprehensive assessments are needed in this vulnerable group to improve survival outcomes and quality of care for cancer patients.
Read More

Survey shows patients with diabetes who follow doctor’s advice more likely to undergo diabetic retinopathy examinations

Diabetic retinopathy is a severe complication of diabetes that can lead to blindness. The Japanese clinical practice guidelines for diabetes recommend that individuals undergo a fundus examination at least once a year to screen for diabetic retinopathy. However, previous studies indicate that fewer than half of individuals with diabetes in Japan undergo regular fundus examinations.
Read More
Top